Brand Name | Status | Last Update |
---|---|---|
cyclo/gaba 10/300 pack | ANDA | 2016-06-22 |
fanatrex | unapproved drug other | 2016-01-07 |
gaba 300-ezs | unapproved drug other | 2020-11-16 |
gabapentin | ANDA | 2024-01-31 |
gabapentin gabapentin | ANDA | 2013-08-23 |
gralise | New Drug Application | 2021-10-01 |
horizant | New Drug Application | 2023-08-29 |
metformin hydrochloride extended release | ANDA | 2017-08-24 |
neurontin | New Drug Application | 2022-07-12 |
neurotin | ANDA | 2021-07-28 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Gabapentin, Gralise, Almatica | |||
7438927 | 2024-02-26 | U-1114 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Postoperative pain | D010149 | — | G89.18 | 7 | 4 | 10 | 28 | 14 | 60 |
Pain | D010146 | EFO_0003843 | R52 | 2 | 5 | 7 | 15 | 15 | 42 |
Healthy volunteers/patients | — | — | — | 11 | — | 1 | 1 | 9 | 22 |
Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | 3 | 3 | 6 | 6 | 3 | 21 |
Neuralgia | D009437 | EFO_0009430 | — | 1 | 4 | 1 | 5 | 6 | 17 |
Sleep initiation and maintenance disorders | D007319 | — | F51.01 | 1 | 4 | 8 | 1 | 2 | 16 |
Diabetic neuropathies | D003929 | EFO_1000783 | — | — | 7 | 4 | 8 | — | 16 |
Hot flashes | D019584 | — | — | — | 2 | 7 | 1 | 5 | 15 |
Chronic pain | D059350 | HP_0012532 | — | — | 4 | 3 | 1 | 4 | 12 |
Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 8 | 3 | 1 | 2 | 12 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 3 | 4 | — | 3 | 9 |
Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | 2 | — | 7 | 9 |
Neoplasms | D009369 | — | C80 | — | 3 | 1 | — | 2 | 6 |
Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 3 | 2 | — | 1 | 5 |
Depression | D003863 | — | F33.9 | — | 1 | 1 | — | 3 | 5 |
Scoliosis | D012600 | EFO_0004273 | M41 | — | — | 3 | — | 1 | 4 |
Postoperative complications | D011183 | — | — | — | 1 | 1 | — | 1 | 3 |
Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | 1 | — | 1 | 3 |
Menopause | D008593 | EFO_0003922 | N95 | — | 1 | 1 | — | 1 | 3 |
Tinnitus | D014012 | HP_0000360 | H93.1 | — | 3 | 1 | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Intervertebral disc displacement | D007405 | EFO_1001800 | — | — | 1 | — | — | 2 | 3 |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 3 | — | — | — | 3 |
Hiv | D006678 | — | O98.7 | — | 1 | — | — | 2 | 3 |
Covid-19 | D000086382 | — | U07.1 | — | 1 | — | — | 1 | 2 |
Male breast neoplasms | D018567 | — | — | — | 1 | — | — | 1 | 2 |
Central nervous system neoplasms | D016543 | — | — | 1 | 2 | — | — | — | 2 |
Cocaine-related disorders | D019970 | — | F14 | — | 2 | — | — | — | 2 |
Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | 1 | — | — | 1 | 2 |
Psychotic disorders | D011618 | — | F20.81 | 1 | 2 | — | — | — | 2 |
Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Refractive errors | D012030 | EFO_0003908 | H52.7 | 1 | — | — | — | — | 1 |
Stomatitis | D013280 | EFO_1001904 | K12.1 | 1 | — | — | — | — | 1 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
Weight loss | D015431 | HP_0001824 | — | 1 | — | — | — | — | 1 |
Taste disorders | D013651 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 2 | 2 |
Hysterectomy | D007044 | EFO_0003881 | — | — | — | — | — | 2 | 2 |
Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 2 | 2 |
Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 2 | 2 |
Vulvodynia | D056650 | — | N94.81 | — | — | — | — | 2 | 2 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | — | — | — | — | 2 | 2 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 2 | 2 |
Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | — | — | 2 | 2 |
Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | — | — | — | — | 2 | 2 |
Pelvic neoplasms | D010386 | — | — | — | — | — | — | 2 | 2 |
Drug common name | Gabapentin |
INN | gabapentin |
Description | Gabapentin is a gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome. It has a role as an anticonvulsant, a calcium channel blocker, an environmental contaminant and a xenobiotic. It is functionally related to a gamma-aminobutyric acid. |
Classification | Small molecule |
Drug class | gabamimetics |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | NCC1(CC(=O)O)CCCCC1 |
PDB | — |
CAS-ID | 60142-96-3 |
RxCUI | — |
ChEMBL ID | CHEMBL940 |
ChEBI ID | 42797 |
PubChem CID | 3446 |
DrugBank | DB00996 |
UNII ID | 6CW7F3G59X (ChemIDplus, GSRS) |